SanBio Company Limited (4592.T)
JPY 762.0
(-4.87%)
JPY 762.0
(-4.87%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 2.25 Billion JPY | -13.81% |
| 2022 | 2.61 Billion JPY | -24.73% |
| 2021 | 3.47 Billion JPY | -30.4% |
| 2020 | 4.99 Billion JPY | 6.82% |
| 2019 | 4.67 Billion JPY | -7.73% |
| 2018 | 5.06 Billion JPY | 16.74% |
| 2017 | 4.34 Billion JPY | 155.7% |
| 2016 | 1.69 Billion JPY | -10.87% |
| 2015 | 1.9 Billion JPY | 3.37% |
| 2014 | 1.84 Billion JPY | -24.41% |
| 2013 | 2.43 Billion JPY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 2.02 Billion JPY | -10.37% |
| 2024 Q2 | 1.98 Billion JPY | -1.69% |
| 2023 Q2 | 2.64 Billion JPY | 26.48% |
| 2023 Q4 | 2.25 Billion JPY | -7.02% |
| 2023 FY | 2.25 Billion JPY | -13.81% |
| 2023 Q1 | 2.09 Billion JPY | -20.03% |
| 2023 Q3 | 2.42 Billion JPY | -8.35% |
| 2022 Q4 | 2.61 Billion JPY | -35.9% |
| 2022 Q3 | 4.08 Billion JPY | -12.54% |
| 2022 FY | 2.61 Billion JPY | -24.73% |
| 2022 Q2 | 4.66 Billion JPY | -16.73% |
| 2022 Q1 | 5.6 Billion JPY | 61.24% |
| 2021 FY | 3.47 Billion JPY | -30.4% |
| 2021 Q4 | 3.47 Billion JPY | -20.78% |
| 2021 Q2 | 4.15 Billion JPY | -10.02% |
| 2021 Q1 | 4.62 Billion JPY | -7.48% |
| 2021 Q3 | 4.38 Billion JPY | 5.53% |
| 2020 Q2 | 4.77 Billion JPY | 7.37% |
| 2020 FY | 4.99 Billion JPY | 6.82% |
| 2020 Q4 | 4.99 Billion JPY | -4.34% |
| 2020 Q3 | 5.22 Billion JPY | 9.29% |
| 2020 Q1 | 4.44 Billion JPY | -4.84% |
| 2019 FY | 4.67 Billion JPY | -7.73% |
| 2019 Q3 | 4.52 Billion JPY | 1.24% |
| 2019 Q4 | 4.67 Billion JPY | 3.38% |
| 2019 Q2 | 4.46 Billion JPY | -8.1% |
| 2019 Q1 | 4.86 Billion JPY | -4.07% |
| 2018 FY | 5.06 Billion JPY | 16.74% |
| 2018 Q4 | 5.06 Billion JPY | 34.91% |
| 2018 Q3 | 3.75 Billion JPY | -5.7% |
| 2018 Q2 | 3.98 Billion JPY | -11.9% |
| 2018 Q1 | 4.52 Billion JPY | 4.16% |
| 2017 Q1 | 2.84 Billion JPY | 67.61% |
| 2017 FY | 4.34 Billion JPY | 155.7% |
| 2017 Q4 | 4.34 Billion JPY | 25.69% |
| 2017 Q3 | 3.45 Billion JPY | 16.03% |
| 2017 Q2 | 2.97 Billion JPY | 4.61% |
| 2016 Q2 | 1.37 Billion JPY | -11.11% |
| 2016 FY | 1.69 Billion JPY | -10.87% |
| 2016 Q3 | 2.01 Billion JPY | 46.51% |
| 2016 Q1 | 1.54 Billion JPY | -18.79% |
| 2016 Q4 | 1.69 Billion JPY | -15.73% |
| 2015 Q2 | 1.98 Billion JPY | 5.48% |
| 2015 Q1 | 1.88 Billion JPY | 2.1% |
| 2015 Q4 | 1.9 Billion JPY | -0.1% |
| 2015 FY | 1.9 Billion JPY | 3.37% |
| 2015 Q3 | 1.9 Billion JPY | -3.91% |
| 2014 FY | 1.84 Billion JPY | -24.41% |
| 2014 Q4 | 1.84 Billion JPY | 0.0% |
| 2013 FY | 2.43 Billion JPY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 3.24 Billion JPY | 30.553% |
| PRISM BioLab Co.,LTD | 63.41 Million JPY | -3455.995% |
| GNI Group Ltd. | 26.34 Billion JPY | 91.44% |
| Linical Co., Ltd. | 10.3 Billion JPY | 78.118% |
| Trans Genic Inc. | 3.81 Billion JPY | 40.856% |
| MEDINET Co., Ltd. | 590.2 Million JPY | -282.053% |
| Soiken Holdings Inc. | 697.02 Million JPY | -223.503% |
| Cytori Cell Research Institute, Inc. | 3.02 Billion JPY | 25.353% |
| AnGes, Inc. | 2.78 Billion JPY | 19.161% |
| OncoTherapy Science, Inc. | 513.6 Million JPY | -339.031% |
| Nxera Pharma Co., Ltd. | 90.38 Billion JPY | 97.505% |
| Immuno-Biological Laboratories Co., Ltd. | 353.27 Million JPY | -538.29% |
| NanoCarrier Co., Ltd. | 1.64 Billion JPY | -36.669% |
| Carna Biosciences, Inc. | 472.35 Million JPY | -377.372% |
| CanBas Co., Ltd. | 91.98 Million JPY | -2351.289% |
| D. Western Therapeutics Institute, Inc. | 1.09 Billion JPY | -106.189% |
| RaQualia Pharma Inc. | 809.83 Million JPY | -178.44% |
| Chiome Bioscience Inc. | 593.73 Million JPY | -279.783% |
| Kidswell Bio Corporation | 4.25 Billion JPY | 46.995% |
| PeptiDream Inc. | 29.11 Billion JPY | 92.255% |
| Oncolys BioPharma Inc. | 566.5 Million JPY | -298.039% |
| Ribomic Inc. | 155.8 Million JPY | -1347.216% |
| Healios K.K. | 11.28 Billion JPY | 80.02% |
| BrightPath Biotherapeutics Co., Ltd. | 251.26 Million JPY | -797.402% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 369 Million JPY | -511.082% |
| Delta-Fly Pharma, Inc. | 241.49 Million JPY | -833.714% |
| StemRIM | 187 Million JPY | -1105.825% |
| CellSource Co., Ltd. | 677.73 Million JPY | -232.708% |
| FunPep Company Limited | 189.32 Million JPY | -1091.023% |
| Kringle Pharma, Inc. | 596.95 Million JPY | -277.732% |
| Stella Pharma Corporation | 1.44 Billion JPY | -56.198% |
| TMS Co., Ltd. | 97.68 Million JPY | -2208.235% |
| Noile-Immune Biotech Inc. | 91.49 Million JPY | -2364.524% |
| Cuorips Inc. | 200.96 Million JPY | -1022.055% |
| K Pharma,Inc. | 209.13 Million JPY | -978.204% |
| Takara Bio Inc. | 11.42 Billion JPY | 80.255% |
| ReproCELL Incorporated | 741.03 Million JPY | -204.291% |
| PhoenixBio Co., Ltd. | 917.71 Million JPY | -145.708% |
| StemCell Institute Inc. | 3.85 Billion JPY | 41.438% |
| Japan Tissue Engineering Co., Ltd. | 908.43 Million JPY | -148.218% |
| CellSeed Inc. | 301.04 Million JPY | -649.017% |